News

GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that the first three patients in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma have been successfully dosed.

Ropidoxuridine (IPdR) is Shuttle Pharma’s lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease.

At Washington, D.C.’s recent Start-Up & Technology Week on October 25th, BioHealth Innovation’s Executive-in-Residence, Luis Gutierrez, led a pivotal panel as part of the life science track sponsored by J-Labs.   It was titled “The Quest for Resources: Unlocking Opportunities for Life Sciences Start-Ups.” Panelists included Ashim Subedee (BARDA DRIVe), Amy Adams (George Mason University), Jack Miner (TEDCO), Sara Adams (DMPED), and Deborah Hemingway (Ecphora Capital), all sharing insights on resource maximization in the BioHealth Capital Region (BHCR).

For Immediate Release: Wednesday, October 23, 2024 – Montgomery County Executive Marc Elrich today announced the launch of a $10 million Job Creation Fund, a new initiative aimed at driving economic growth and encouraging job creation in the County’s key industries. The program, established by a special appropriation through County Council Resolution 20-491, led by Council President Andrew Friedson, will provide financial incentives of up to $500,000 for businesses that create high-paying jobs in sectors such as advanced technology, life sciences, cybersecurity, hospitality and quantum computing.

Eligible companies can receive $10,000 for each new job created, with increased incentives for businesses located in disadvantaged areas as defined by the County’s Community Equity Index. The fund is designed to build on Montgomery County’s reputation as a hub for innovation and economic opportunity, while also supporting job creation that strengthens the local workforce.

The invited teams highlight the broad interest in the NSF Engines program and show great promise in building regional ecosystems that will accelerate breakthrough technologies, leading to economic development.

The U.S. National Science Foundation Regional Innovation Engines (NSF Engines) program announced that 71 teams spanning nearly every state and territory in the nation are advancing to the next stage of the second-ever competition. The program is charting a new frontier for American innovation pursuant to the bipartisan “CHIPS and Science Act of 2022.” The teams selected to submit full proposals stand to build upon an inaugural cohort of regions nationwide that are bringing technology-driven economic and workforce development to all parts of the United States. Explore the interactive map.  

Baltimore, MD (October 24th, 2024) – Sonavex, Inc., a privately held medical device company with ultrasound technologies that deliver quantitative blood flow and other critical vascular data at the point of care, announced the closing of its $15 million Series A-2 financing. The round attracted several new institutional investors, strong participation from existing shareholders, and industry veterans in vascular and dialysis. New investors include Unorthodox Ventures, GenHenn Capital, JSTAR Capital, Oakwood Circle Ventures, Riptide Ventures and Partners Investment.

COLUMBIA, Md., (October 24, 2024) –– TEDCO, Maryland’s economic engine for technology companies, announces the “Breaking Barriers and Building Futures: The Evolution of Women Entrepreneurs in Maryland” session at the 10^th Entrepreneur Expo, taking place on December 4, 2024, at the Renaissance Baltimore Harborplace Hotel.

The dynamic growth of women-led entrepreneurship in Maryland will take center stage in this insightful panel discussion featuring Jasmine Clemons, director of the Maryland Board of Public Works, Danette Nguyen, managing director of the Maryland Women’s Business Center and Samantha Scott, PhD, CEO and founder of JuneBrain. The conversation will explore the unique challenges women face in today’s business landscape, with a particular focus on access to capital, scaling strategies and the support systems necessary for sustained success.

ROCKVILLE, Md., Oct. 23, 2024 /PRNewswire/ — Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health (NIH) to enable infrastructure improvement that will scale GMP production and accelerate quality assurance (QA) and quality control (QC), significantly enhancing its biologics drug manufacturing capabilities. This Commercial Readiness Pilot (CRP) Program SBIR award will also support Phase 2 clinical GMP manufacturing to advance Rise Therapeutics’ R-3750 program currently completing a Phase 1 proof-of-concept clinical trial in patients suffering from ulcerative colitis.

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS), today announced the teams selected by its Sprint for Women’s Health to receive awards. The agency committed over $110 million to fund solutions for health conditions that uniquely or disproportionately affect women. This effort will advance the White House Initiative on Women’s Health Research and help spur the type of innovation and private sector engagement long needed to improve women’s health.  

WASHINGTON, D.C., Oct. 23, 2024 (GLOBE NEWSWIRE) — Pain assessment in medicine often relies on imprecise visual rating scales featuring smiling or crying faces, frustrating patients and physicians alike. Children’s National Hospital researchers aim to change this with a new device designed to precisely measure pain, backed by an $8-million award from the Advanced Research Projects Agency for Health (ARPA-H) Sprint for Women’s Health.